Browsing by Author "Singh, Sahib"

Now showing 1 - 5 of 5
  • Thumbnail Image
    Item
    Basic Principles and Role of Endoscopic Ultrasound in Diagnosis and Differentiation of Pancreatic Cancer from Other Pancreatic Lesions: A Comprehensive Review of Endoscopic Ultrasound for Pancreatic Cancer
    (MDPI, 2024-04-28) Dahiya, Dushyant Singh; Shah, Yash R.; Ali, Hassam; Chandan, Saurabh; Gangwani, Manesh Kumar; Canakis, Andrew; Ramai, Daryl; Hayat, Umar; Pinnam, Bhanu Siva Mohan; Iqbal, Amna; Malik, Sheza; Singh, Sahib; Jaber, Fouad; Alsakarneh, Saqr; Mohamed, Islam; Ali, Meer Akbar; Al-Haddad, Mohammad; Inamdar, Sumant; Medicine, School of Medicine
    Pancreatic cancer is one of the leading causes of cancer-related deaths worldwide. Pancreatic lesions consist of both neoplastic and non-neoplastic lesions and often pose a diagnostic and therapeutic challenge due to similar clinical and radiological features. In recent years, pancreatic lesions have been discovered more frequently as incidental findings due to the increased utilization and widespread availability of abdominal cross-sectional imaging. Therefore, it becomes imperative to establish an early and appropriate diagnosis with meticulous differentiation in an attempt to balance unnecessary treatment of benign pancreatic lesions and missing the opportunity for early intervention in malignant lesions. Endoscopic ultrasound (EUS) has become an important diagnostic modality for the identification and risk stratification of pancreatic lesions due to its ability to provide detailed imaging and acquisition of tissue samples for analysis with the help of fine-needle aspiration/biopsy. The recent development of EUS-based technology, including contrast-enhanced endoscopic ultrasound, real-time elastography–endoscopic ultrasound, miniature probe ultrasound, confocal laser endomicroscopy, and the application of artificial intelligence has significantly augmented the diagnostic accuracy of EUS as it enables better evaluation of the number, location, dimension, wall thickness, and contents of these lesions. This article provides a comprehensive overview of the role of the different types of EUS available for the diagnosis and differentiation of pancreatic cancer from other pancreatic lesions while discussing their key strengths and important limitations.
  • Thumbnail Image
    Item
    Early and Late Readmissions of Radiation Proctitis in the United States: Are We Getting Better?
    (MDPI, 2024-01-12) Dahiya, Dushyant Singh; Pinnam, Bhanu Siva Mohan; Ishaya, Michelle; Chandan, Saurabh; Gangwani, Manesh Kumar; Singh, Sahib; Ali, Hassam; Sohail, Amir Humza; Canakis, Andrew; Ramai, Daryl; Zelt, Christina; Inamdar, Sumant; Al-Haddad, Mohammad; Rojas-DeLeon, Mariajose; Sharma, Neil R.; Medicine, School of Medicine
    Background/Aims: Radiation proctitis (RP), a well-known complication of pelvic radiation therapy, may lead to recurrent hospitalizations. We aimed to assess readmissions of RP in the United States. Methods: We analyzed the Nationwide Readmission Database from 2016 to 2020 to identify all 30-, 60-, and 90-day readmissions of RP in the United States. Hospitalization characteristics, predictors, clinical outcomes, and healthcare burdens were assessed. Results: From 2016 to 2020, we noted a declining trend of 30-, 60-, and 90-day readmissions of RP in the US. However, the all-cause 30-, 60-, and 90-day readmission rates of RP were still high at 13.7%, 19.4%, and 23.16%, respectively. On readmission, RP was identified as the admitting diagnosis in only 20.61%, 17.87%, and 15.76% of 30-, 60-, and 90-day readmissions, respectively. The mean age for all readmissions was 70 years with a significant male dominance. Lower endoscopy at index admission reduced the risk of readmissions within 90 days, but this was not statistically significant. However, the Charlson Comorbidity Index (CCI) score was an independent predictor of all readmissions. Furthermore, the mean length of stay was 5.57 (95% CI 5.15-6), 5.50 (95% CI 5.12-5.89), and 5.47 (95% CI 5.07-5.87) days and the mean hospitalization charge was USD 60,451 (95% CI USD 54,728-66,174), USD 62,671 (95% CI USD 57,326-68,015), and USD 62,144 (95% CI USD 57,144-67,144) for 30-, 60-, and 90-day readmissions. The all-cause inpatient mortality for 30-, 60-, and 90-day readmissions was 3.58%, 3.89%, and 3.46%, respectively. Conclusions: RP readmissions are a significant healthcare burden. Further efforts must be directed toward improving management strategies to reduce readmission rates.
  • Thumbnail Image
    Item
    Endoscopic Ultrasound-Guided Treatments for Pancreatic Cancer: Understanding How Endoscopic Ultrasound Has Revolutionized Management of Pancreatic Cancer
    (MDPI, 2024-12-30) Singh, Sahib; Facciorusso, Antonio; Vinayek, Rakesh; Dutta, Sudhir; Dahiya, Dushyant Singh; Aswath, Ganesh; Sharma, Neil; Inamdar, Sumant; Medicine, School of Medicine
    Pancreatic cancer is associated with high rates of morbidity and mortality. Endoscopic ultrasound (EUS)-guided biopsy has become the standard diagnostic modality per the guidelines. The use of EUS has been growing for providing various treatments in patients with pancreatic cancers: biliary and gallbladder drainage for those with malignant biliary obstruction, gastroenterostomy for malignant gastric outlet obstruction, celiac plexus/ganglia neurolysis for pain control, radiofrequency ablation, placement of fiducial markers, and injection of local chemotherapeutic agents. In this review, we explore the recent clinical studies evaluating the EUS-guided treatments in pancreatic cancer.
  • Thumbnail Image
    Item
    Impact of Artificial Intelligence on Pancreaticobiliary Endoscopy
    (MDPI, 2025-01-24) Jain, Aryan; Pabba, Mayur; Jain, Aditya; Singh, Sahib; Ali, Hassam; Vinayek, Rakesh; Aswath, Ganesh; Sharma, Neil; Inamdar, Sumant; Facciorusso, Antonio; Medicine, School of Medicine
    Pancreaticobiliary diseases can lead to significant morbidity and their diagnoses rely on imaging and endoscopy which are dependent on operator expertise. Artificial intelligence (AI) has seen a rapid uptake in the field of luminal endoscopy, such as polyp detection during colonoscopy. However, its use for pancreaticobiliary endoscopic modalities such as endoscopic ultrasound (EUS) and cholangioscopy remains scarce, with only few studies available. In this review, we delve into the current evidence, benefits, limitations, and future scope of AI technologies in pancreaticobiliary endoscopy.
  • Thumbnail Image
    Item
    Remimazolam for sedation in gastrointestinal endoscopy: A comprehensive review
    (Baishideng, 2024) Dahiya, Dushyant Singh; Kumar, Ganesh; Parsa, Syeda; Gangwani, Manesh Kumar; Ali, Hassam; Sohail, Amir Humza; Alsakarneh, Saqr; Hayat, Umar; Malik, Sheza; Shah, Yash R.; Mohan Pinnam, Bhanu Siva; Singh, Sahib; Mohamed, Islam; Rao, Adishwar; Chandan, Saurabh; Al-Haddad, Mohammad; Medicine, School of Medicine
    Worldwide, a majority of routine endoscopic procedures are performed under some form of sedation to maximize patient comfort. Propofol, benzodiazepines and opioids continue to be widely used. However, in recent years, Remimazolam is gaining immense popularity for procedural sedation in gastrointestinal (GI) endoscopy. It is an ultra-short-acting benzodiazepine sedative which was approved by the Food and Drug Administration in July 2020 for use in procedural sedation. Remimazolam has shown a favorable pharmacokinetic and pharmacodynamic profile in terms of its non-specific metabolism by tissue esterase, volume of distribution, total body clearance, and negligible drug-drug interactions. It also has satisfactory efficacy and has achieved high rates of successful sedation in GI endoscopy. Furthermore, studies have demonstrated that the efficacy of Remimazolam is non-inferior to Propofol, which is currently a gold standard for procedural sedation in most parts of the world. However, the use of Propofol is associated with hemodynamic instability and respiratory depression. In contrast, Remimazolam has lower incidence of these adverse effects intra-procedurally and hence, may provide a safer alternative to Propofol in procedural sedation. In this comprehensive narrative review, highlight the pharmacologic characteristics, efficacy, and safety of Remimazolam for procedural sedation. We also discuss the potential of Remimazolam as a suitable alternative and how it can shape the future of procedural sedation in gastroenterology.